Genome‐wide mapping of plasma protein QTLs identifies putatively causal genes and pathways for cardiovascular disease

[1]  Stephen Burgess,et al.  Genomic atlas of the human plasma proteome , 2018, Nature.

[2]  Valeriia Haberland,et al.  The MR-Base platform supports systematic causal inference across the human phenome , 2018, eLife.

[3]  Kathryn Demanelis,et al.  Co-occurring expression and methylation QTLs allow detection of common causal variants and shared biological mechanisms , 2018, Nature Communications.

[4]  J. Ge,et al.  Cysteine Protease Cathepsins in Atherosclerotic Cardiovascular Diseases , 2017, Journal of atherosclerosis and thrombosis.

[5]  Erdogan Taskesen,et al.  Functional mapping and annotation of genetic associations with FUMA , 2017, Nature Communications.

[6]  J. Danesh,et al.  Efficiency and safety of varying the frequency of whole blood donation (INTERVAL): a randomised trial of 45 000 donors , 2017, The Lancet.

[7]  A. Maleki,et al.  Paraoxonase 1 Activity, Lipid Profile, and Atherogenic Indexes Status in Coronary Heart Disease. , 2017, Reports of biochemistry & molecular biology.

[8]  J. Danesh,et al.  Association analyses based on false discovery rate implicate new loci for coronary artery disease , 2017, Nature Genetics.

[9]  Kamran Shaffi,et al.  Rediscovering Beta-2 Microglobulin As a Biomarker across the Spectrum of Kidney Diseases , 2017, Front. Med..

[10]  Wei-Jei Wang,et al.  Associations among Serum Beta 2 Microglobulin, Malnutrition, Inflammation, and Advanced Cardiovascular Event in Patients with Chronic Kidney Disease , 2017, Journal of clinical laboratory analysis.

[11]  A. Morris,et al.  Mapping of 79 loci for 83 plasma protein biomarkers in cardiovascular disease , 2017, PLoS genetics.

[12]  W. Cui,et al.  High levels of serum β2-microglobulin predict severity of coronary artery disease , 2017, BMC Cardiovascular Disorders.

[13]  Christian Gieger,et al.  Connecting genetic risk to disease end points through the human blood plasma proteome , 2016, Nature Communications.

[14]  A. Passaro,et al.  Interleukin-6 “Trans-Signaling” and Ischemic Vascular Disease: The Important Role of Soluble gp130 , 2017, Mediators of inflammation.

[15]  R. Stocker,et al.  The roles of myeloperoxidase in coronary artery disease and its potential implication in plaque rupture , 2016, Redox report : communications in free radical research.

[16]  Roby Joehanes,et al.  Integrated genome-wide analysis of expression quantitative trait loci aids interpretation of genomic association studies , 2017, Genome Biology.

[17]  Cathy H. Wu,et al.  UniProt: the Universal Protein knowledgebase , 2004, Nucleic Acids Res..

[18]  R. Collins,et al.  No Association of Coronary Artery Disease with X-Chromosomal Variants in Comprehensive International Meta-Analysis , 2016, Scientific Reports.

[19]  D. Saleheen,et al.  Using Mendelian Randomization Studies to Assess Causality and Identify New Therapeutic Targets in Cardiovascular Medicine , 2016, Current Genetic Medicine Reports.

[20]  J. Pankow,et al.  ABO blood group associations with markers of endothelial dysfunction in the Multi-Ethnic Study of Atherosclerosis. , 2016, Atherosclerosis.

[21]  Steven P. Gygi,et al.  Defining the consequences of genetic variation on a proteome-wide scale , 2016, Nature.

[22]  K. Frazer,et al.  Associations Between Common and Rare Exonic Genetic Variants and Serum Levels of 20 Cardiovascular-Related Proteins , 2016, Circulation. Cardiovascular genetics.

[23]  D. Harrison,et al.  Activation of Human T Cells in Hypertension: Studies of Humanized Mice and Hypertensive Humans. , 2016, Hypertension.

[24]  Dermot F. Reilly,et al.  Coding variation in ANGPTL4, LPL, and SVEP1 and the risk of coronary disease , 2018 .

[25]  M. Madhur,et al.  Linking inflammation and hypertension via LNK/SH2B3 , 2016, Current opinion in nephrology and hypertension.

[26]  Gabor T. Marth,et al.  A global reference for human genetic variation , 2015, Nature.

[27]  J. Danesh,et al.  A comprehensive 1000 Genomes-based genome-wide association meta-analysis of coronary artery disease , 2016 .

[28]  E. Boerwinkle,et al.  Quantitative Influence of ABO Blood Groups on Factor VIII and Its Ratio to von Willebrand Factor, Novel Observations from an ARIC Study of 11,673 Subjects , 2015, PloS one.

[29]  G. Kempermann.  Faculty Opinions recommendation of Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. , 2015 .

[30]  Jun S. Liu,et al.  The Genotype-Tissue Expression (GTEx) pilot analysis: Multitissue gene regulation in humans , 2015, Science.

[31]  Andrew D. Johnson,et al.  Integrative network analysis reveals molecular mechanisms of blood pressure regulation , 2015, Molecular systems biology.

[32]  Andrew D. Johnson,et al.  A Meta-analysis of Gene Expression Signatures of Blood Pressure and Hypertension , 2015, PLoS genetics.

[33]  Ruedi Aebersold,et al.  Quantitative variability of 342 plasma proteins in a human twin population , 2015 .

[34]  B. Astor,et al.  Association of kidney function and albuminuria with prevalent and incident hypertension: the Atherosclerosis Risk in Communities (ARIC) study. , 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[35]  Andrew D. Johnson,et al.  Integrative network analysis reveals molecular mechanisms of blood pressure regulation. , 2015, Molecular systems biology.

[36]  Jonathan Mant,et al.  The INTERVAL trial to determine whether intervals between blood donations can be safely and acceptably decreased to optimise blood supply: study protocol for a randomised controlled trial , 2014, Trials.

[37]  Ulf Gyllensten,et al.  Strong effects of genetic and lifestyle factors on biomarker variation and use of personalized cutoffs , 2014, Nature Communications.

[38]  Christopher D. Brown,et al.  Identification and Validation of Genetic Variants that Influence Transcription Factor and Cell Signaling Protein Levels , 2014, American journal of human genetics.

[39]  F. Pileggi,et al.  Lipoprotein (a): Structure, Pathophysiology and Clinical Implications , 2014, Arquivos brasileiros de cardiologia.

[40]  D. Levy,et al.  Protein Biomarkers of New-Onset Cardiovascular Disease: Prospective Study From the Systems Approach to Biomarker Research in Cardiovascular Disease Initiative , 2014, Arteriosclerosis, thrombosis, and vascular biology.

[41]  Jennifer G. Robinson,et al.  Association of low-frequency and rare coding-sequence variants with blood lipids and coronary heart disease in 56,000 whites and blacks. , 2014, American journal of human genetics.

[42]  David S. Wishart,et al.  DrugBank 4.0: shedding new light on drug metabolism , 2013, Nucleic Acids Res..

[43]  C. Wallace,et al.  Bayesian Test for Colocalisation between Pairs of Genetic Association Studies Using Summary Statistics , 2013, PLoS genetics.

[44]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[45]  Eric Boerwinkle,et al.  Best Practices and Joint Calling of the HumanExome BeadChip: The CHARGE Consortium , 2013, PloS one.

[46]  Andrew D. Johnson,et al.  Gene Expression Signatures of Coronary Heart Disease , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[47]  Ellen T. Gelfand,et al.  The Genotype-Tissue Expression (GTEx) project , 2013, Nature Genetics.

[48]  Stefan Enroth,et al.  Identification of genetic variants influencing the human plasma proteome , 2013, Proceedings of the National Academy of Sciences.

[49]  J. McMurray,et al.  Soluble Glycoprotein 130 Predicts Fatal Outcomes in Chronic Heart Failure: Analysis From the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) , 2013, Circulation. Heart failure.

[50]  F. Contaldo,et al.  Butyrylcholinesterase as a prognostic marker: a review of the literature , 2012, Journal of cachexia, sarcopenia and muscle.

[51]  Magda Tsolaki,et al.  Identification of cis-regulatory variation influencing protein abundance levels in human plasma. , 2012, Human molecular genetics.

[52]  A. Zwinderman,et al.  Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. , 2012, JAMA.

[53]  R. Durbin,et al.  Using probabilistic estimation of expression residuals (PEER) to obtain increased power and interpretability of gene expression analyses , 2012, Nature Protocols.

[54]  C. Furberg,et al.  A Meta-Analysis of Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, and Apolipoprotein B as Markers of Cardiovascular Risk , 2011, Circulation. Cardiovascular quality and outcomes.

[55]  Thomas W. Mühleisen,et al.  Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease , 2011, Nature Genetics.

[56]  H. Feldman,et al.  Sortilin-Mediated Endocytosis Determines Levels of the Frontotemporal Dementia Protein, Progranulin , 2010, Neuron.

[57]  J. Manson,et al.  Novel proteins associated with risk for coronary heart disease or stroke among postmenopausal women identified by in-depth plasma proteome profiling , 2010, Genome Medicine.

[58]  L. Ouafik,et al.  Soluble CD146 displays angiogenic properties and promotes neovascularization in experimental hind-limb ischemia. , 2010, Blood.

[59]  Leopold Parts,et al.  A Bayesian Framework to Account for Complex Non-Genetic Factors in Gene Expression Levels Greatly Increases Power in eQTL Studies , 2010, PLoS Comput. Biol..

[60]  Asaf Bitton,et al.  Growing epidemic of coronary heart disease in low- and middle-income countries. , 2010, Current problems in cardiology.

[61]  Xiantao Song,et al.  Relationship between plasma cathepsin S and cystatin C levels and coronary plaque morphology of mild to moderate lesions: an in vivo study using intravascular ultrasound. , 2009, Chinese medical journal.

[62]  M. Nobuyoshi,et al.  Progranulin expression in advanced human atherosclerotic plaque. , 2009, Atherosclerosis.

[63]  Mark I. McCarthy,et al.  A Genome-Wide Association Study Identifies Protein Quantitative Trait Loci (pQTLs) , 2008, PLoS genetics.

[64]  Qiong Yang,et al.  The Third Generation Cohort of the National Heart, Lung, and Blood Institute's Framingham Heart Study: design, recruitment, and initial examination. , 2007, American journal of epidemiology.

[65]  PaulHolvoet,et al.  Human Paraoxonase-1 Overexpression Inhibits Atherosclerosis in a Mouse Model of Metabolic Syndrome , 2006 .

[66]  J. González-Porras,et al.  A nonsense polymorphism in the protein Z-dependent protease inhibitor increases the risk for venous thrombosis. , 2006, Blood.

[67]  P. Holvoet,et al.  Human Paraoxonase-1 Overexpression Inhibits Atherosclerosis in a Mouse Model of Metabolic Syndrome , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[68]  Joseph H Abramson,et al.  Butyrylcholinesterase activity, cardiovascular risk factors, and mortality in middle-aged and elderly men and women in Jerusalem. , 2006, Clinical chemistry.

[69]  P. Wadhwa,et al.  Validation and comparison of luminex multiplex cytokine analysis kits with ELISA: determinations of a panel of nine cytokines in clinical sample culture supernatants. , 2005, Journal of reproductive immunology.

[70]  C. Gieger,et al.  KORA-gen - Resource for Population Genetics, Controls and a Broad Spectrum of Disease Phenotypes , 2005 .

[71]  Leigh Anderson,et al.  Candidate‐based proteomics in the search for biomarkers of cardiovascular disease , 2005, The Journal of physiology.

[72]  Cathy H. Wu,et al.  UniProt: the Universal Protein knowledgebase , 2004, Nucleic Acids Res..

[73]  S. Ebrahim,et al.  'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? , 2003, International journal of epidemiology.

[74]  K. Rockwood,et al.  Relation between butyrylcholinesterase K variant, paraoxonase 1 (PON1) Q and R and apolipoprotein E epsilon 4 genes in early-onset coronary artery disease. , 2002, Clinical biochemistry.

[75]  W James Gauderman,et al.  Sample size requirements for matched case‐control studies of gene–environment interaction , 2002, Statistics in medicine.

[76]  D. Vignali,et al.  Simultaneous quantitation of 15 cytokines using a multiplexed flow cytometric assay. , 1999, Journal of immunological methods.

[77]  P. Allhoff,et al.  The Framingham Offspring Study , 1991 .

[78]  J. Bluestone,et al.  Activation of human T cells in vivo following treatment of transplant recipients with OKT3. , 1990, Transplantation.

[79]  W. Kannel,et al.  ABO blood group and cardiovacular disease: the Framingham study. , 1976, Atherosclerosis.

[80]  W. Kannel,et al.  The Framingham Offspring Study. Design and preliminary data. , 1975, Preventive medicine.

[81]  T. Dawber,et al.  Epidemiological approaches to heart disease: the Framingham Study. , 1951, American journal of public health and the nation's health.